SAFETY SUBGROUP ANALYSES FROM THE CECOG PHASE III TURANDOT TRIAL: FIRST-LINE BEVACIZUMAB (BEV) IN COMBINATION WITH CAPECITABINE (X) OR PACLITAXEL (P) FOR HER2-NEGATIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (LR/MBC)

被引：0

作者：

Lang, I. ^{[1
]}

Inbar, M. ^{[2
]}

Greil, R. ^{[3
]}

Kahan, Z. ^{[4
]}

Beslija, S. ^{[5
]}

Steger, G. G. ^{[6
]}

Stemmer, S. M. ^{[7
]}

Zvribule, Z. ^{[8
]}

Kaufman, B. ^{[9
]}

Zielinski, C. ^{[10
,11
]}

机构：

[1] Natl Inst Oncol, Dept Med Oncol & Clin Pharmacol B, Budapest, Hungary

[2] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel

[3] Med Univ Salzburg, Dept Med, Salzburg, Austria

[4] Univ Med Sch Szeged, Szeged, Hungary

[5] Inst Oncol, Sarajevo, Bosnia & Herceg

[6] Med Univ Vienna, Med & Canc Ctr, Vienna, Austria

[7] Davidoff Ctr, Petah Tiqwa, Israel

[8] Riga Eastern Hosp, Latvian Ctr Oncol, Riga, Latvia

[9] Chaim Sheba Med Ctr, Div Oncol, Ramat Gan, Israel

[10] Univ Hosp, Dept Med 1, Vienna, Austria

[11] Ctr Canc, Vienna, Austria

来源：

ANNALS OF ONCOLOGY | 2010年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：98 / 98

页数：1

共 50 条

[41] Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab [J].

Pizzuti, Laura ;

Sergi, Domenico ;

Sperduti, Isabella ;

Di Lauro, Luigi ;

Mazzotta, Marco ;

Botti, Claudio ;

Izzo, Fiorentino ;

Marchetti, Luca ;

Tomao, Silverio ;

Marchetti, Paolo ;

Natoli, Clara ;

Grassadonia, Antonino ;

Gamucci, Teresa ;

Mentuccia, Lucia ;

Magnolfi, Emanuela ;

Vaccaro, Angela ;

Cassano, Alessandra ;

Rossi, Ernesto ;

Botticelli, Andrea ;

Sini, Valentina ;

Sarobba, Maria G. ;

Fabbri, Maria Agnese ;

Moscetti, Luca ;

Astone, Antonio ;

Michelotti, Andrea ;

De Angelis, Claudia ;

Bertolini, Ilaria ;

Angelini, Francesco ;

Ciliberto, Gennaro ;

Maugeri-Sacca, Marcello ;

Giordano, Antonio ;

Barba, Maddalena ;

Vici, Patrizia .

CANCER BIOLOGY & THERAPY, 2018, 19 (04) :328-334

[42] Plasma VEGF-a, angiopoietin-2 (ANG2) and soluble(s)TIE2 in patients (pts) with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X) [J].

Lam, Siu W. ;

de Groot, Steffen M. ;

Honkoop, Aafke H. ;

Nota, Nienke M. ;

Jager, A. ;

van der Velden, Ankle M. T. ;

Bos, Monique M. E. M. ;

Linn, Sabine C. ;

Van Den Bosch, J. ;

Kroep, Judith R. ;

Braun, J. J. ;

de Haas, Richard R. ;

Smorenburg, Carolien H. ;

de Graaf, Hiltje ;

Portielje, Johanna Elisabeth A. ;

Los, Maartje ;

de Gooyer, Domingo ;

van Tinteren, Harm ;

Boven, Epie .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

[43] Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer [J].

Martin, Miguel ;

Makhson, Anatoly ;

Gligorov, Joseph ;

Lichinitser, Mikhail ;

Lluch, Ana ;

Semiglazov, Vladimir ;

Scotto, Nana ;

Mitchell, Lada ;

Tjulandin, Sergei .

ONCOLOGIST, 2012, 17 (04) :469-475

[44] Bevacizumab (BV) in combination with chemotherapy in the treatment of HER2-negative metastatic breast cancer (mBC): PFS subgroup results from two phase III studies [J].

Glaspy, J. ;

Dieras, V. ;

Brufsky, A. ;

Miles, D. W. ;

Phan, S. C. ;

O'Shaughnessy, J. .

EJC SUPPLEMENTS, 2010, 8 (03) :202-202

[45] Phase II trial evaluating the combination of eribulin (E) plus bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study [J].

Hardy-Bessard, A-C. ;

Brocard, F. ;

Leheurteur, M. ;

Melis, A. ;

Dauba, J. ;

Lortholary, A. ;

You, B. ;

Guardiola, E. ;

Grenier, J. ;

Martin-Babau, J. ;

Meunier, J. ;

Follana, P. ;

Savoye, A-M. ;

Mercier-Blas, A. ;

Marti, A. ;

Despax, R. ;

Barbier, N. ;

Gane, N. ;

Ardisson, P. ;

Segura-Djezzar, C. .

ANNALS OF ONCOLOGY, 2016, 27

[46] First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: First PFS analysis. [J].

Salvador, J. ;

Jaen, A. ;

Ciruelos, E. M. ;

Codes, M. ;

Gil, M. ;

Murias, A. ;

Galan, A. ;

De la Haba, J. R. ;

Jara, C. ;

Bayo, J. L. ;

Baena, J. M. ;

Casal, J. ;

Mel, J. R. ;

Blancas, I. ;

Gonzalez, E. ;

Perez, D. ;

Manso, L. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[47] Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC) [J].

Conlin, A. K. ;

Hudis, C. A. ;

Bach, A. ;

Moynahan, M. ;

Lake, D. ;

Forero-Torres, A. ;

Wright, G. ;

Hackney, M. ;

Clawson, A. ;

Seidman, A. D. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

[48] Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study [J].

Dieras, Veronique ;

Wildiers, Hans ;

Jassem, Jacek ;

Dirix, Luc Y. ;

Guastalla, Jean-Paul ;

Bono, Petri ;

Hurvitz, Sara A. ;

Goncalves, Anthony ;

Romieu, Gilles ;

Limentani, Steven A. ;

Jerusalem, Guy ;

Lakshmaiah, K. C. ;

Roche, Henri ;

Sanchez-Rovira, Pedro ;

Pienkowski, Tadeusz ;

Segui Palmer, Miguel Angel ;

Li, Ai ;

Sun, Yu-Nien ;

Pickett, Cheryl A. ;

Slamon, Dennis J. .

BREAST, 2015, 24 (03) :182-190

[49] Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer [J].

Borson, Rachel ;

Harker, Graydon ;

Reeves, James ;

Beck, Thaddeus ;

Hager, Steven ;

Horvath, William ;

Jones, Michael ;

Tillinghast, Guy ;

Arrowsmith, Edward ;

Harrer, Grant ;

Kudrik, Fred J. ;

Malamud, Stephen C. ;

Bromund, Jane ;

Zeigler, Haoyue ;

Tai, Datchen Fritz ;

Kornberg, Lori J. ;

Obasaju, Coleman ;

Orlando, Mauro ;

Yardley, Denise A. .

CLINICAL BREAST CANCER, 2012, 12 (05) :322-330

[50] Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer [J].

Wu, Qiuji ;

Wang, Xinyuan ;

Zhang, Mengxi ;

Liao, Weiting ;

Wang, Feng ;

Li, Qiu .

ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (04) :153-159

← 1 2 3 4 5 →